AZD1208
AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity. Pan-PIM kinase inhibitor AZD1208 inhibits the activities of PIM1, PIM2 and PIM3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, thereby causing cell cycle arrest and inducing apoptosis in cells that overexpress PIMs. The growth inhibition of several leukemia cell lines by this agent is correlated with the expression levels of PIM1, which is the substrate of STAT transcription factors. PIM kinases are downstream effectors of many cytokine and growth factor signaling pathways and are upregulated in various malignancies.
Product Specifications
CAS Number
1204144-28-4
Product Name Alternative
AZD1208 | AZD-1208
Purity
>98% (HPLC)
Solubility
DMSO : 28.5 mg/mL 75.10 mM
Smiles
C1 (c (cccc1/C=C/1\SC (=O) NC1=O) c1ccccc1) N1CCC[C@H] (C1) N
Molecular Formula
C21H21N3O2S
Molecular Weight
379.48
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
5-[[2-[ (3R) -3-Aminopiperidin-1-yl]biphenyl-3-yl]methylidene]-1,3-thiazolidine-2,4-dione
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Beta Actin Recombinant Rabbit mAb, BF555 conjugated
SP3 (Sp3 Transcription Factor, DKFZp686O1631, SPR-2) (MaxLight 750) discontinued
Recombinant Talpa europaea Alpha-2B adrenergic receptor (ADRA2B)
Recombinant Talpa europaea Alpha-2B adrenergic receptor (ADRA2B)
Recombinant Talpa europaea Alpha-2B adrenergic receptor (ADRA2B)